Related Experiment Video
Updated: Aug 16, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge
C J Davis1, P A Gurbel, W A Gattis
1Sinai Center for Thrombosis Research, Sinai Hospital, Baltimore, MD 21215, USA.
Insights
Congestive heart failure (CHF) involves complex hemostatic abnormalities. This review explores platelet activation, thrombin generation, and fibrinolysis in CHF, assessing anticoagulant and antiplatelet therapy potential.
Area of Science:
- Cardiology
- Hematology
- Pathophysiology
Background:
- Congestive heart failure (CHF) remains a leading cause of morbidity and mortality.
- Current understanding of CHF pathophysiology heavily relies on neurohormonal mechanisms.
- Pharmacologic interventions like ACE inhibitors and beta-blockers have improved outcomes, but consensus on anticoagulants/antiplatelets is lacking.
Purpose of the Study:
- To review current knowledge on hemostatic abnormalities in CHF patients.
- To discuss platelet activation, thrombin generation, fibrinolysis, and endothelial dysfunction in CHF.
- To evaluate the potential role of anticoagulants and antiplatelet agents in managing these abnormalities.
Main Methods:
- Literature review of studies on hemostasis in congestive heart failure.
- Analysis of research on platelet function, coagulation, and fibrinolysis in CHF.
- Examination of clinical trial data and observational studies regarding anticoagulant/antiplatelet therapy in CHF.
Main Results:
- CHF is associated with altered hemostasis, suggesting a prothrombotic state.
- Mechanisms include platelet activation, increased thrombin generation, and impaired fibrinolysis.
- Endothelial dysfunction also plays a role in the hemostatic imbalance of CHF.
Conclusions:
- The prothrombotic state in CHF may contribute to disease pathogenesis and progression.
- Anticoagulant and/or antiplatelet agents warrant further investigation for their potential therapeutic role.
- Targeting hemostatic abnormalities could offer new strategies for managing congestive heart failure.
Abstract:
Knowledge of the pathogenesis of congestive heart failure (CHF) has improved greatly in recent years. However, this disease continues to cause one of the highest morbidities and mortalities in the Western world. The pathophysiology of heart failure is complex and much of our understanding revolves strictly around the neurohormonal mechanisms involved. Various pharmacologic interventions have significantly improved morbidity and include ACE inhibitors, beta-blockers, diuretics, and inotropic agents. Yet, no consensus has been reached regarding the use of anticoagulants or antiplatelet agents. It has been suggested that CHF is associated with altered hemostasis, but whether this prothrombotic state contributes to the pathogenesis and progression of the disease is unknown. The purpose of this review article is to discuss our current knowledge of platelet activation, thrombin generation, fibrinolysis, and endothelial dysfunction in CHF patients, and the potential role of anticoagulants and/or antiplatelet agents in preventing these hemostatic abnormalities.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations

